AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Chemerin-like receptor 1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We employ our advanced, specialised process to create targeted libraries for receptors.

 Fig. 1. The sreening workflow of Receptor.AI

It features thorough molecular simulations of the receptor within its native membrane environment, complemented by ensemble virtual screening that considers its conformational mobility. For dimeric or oligomeric receptors, the full functional complex is constructed, and tentative binding sites are determined on and between the subunits to cover the entire spectrum of potential mechanisms of action.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q99788

UPID:

CML1_HUMAN

Alternative names:

Chemokine-like receptor 1; G-protein coupled receptor ChemR23; G-protein coupled receptor DEZ

Alternative UPACC:

Q99788; A8K6Y5; O75748; Q3KP37; Q5U0H0; Q99789

Background:

Chemerin-like receptor 1, also known as Chemokine-like receptor 1, G-protein coupled receptor ChemR23, and G-protein coupled receptor DEZ, plays a pivotal role in mediating cellular responses to chemoattractant adipokine chemerin/RARRES2 and omega-3 fatty acid derived molecule resolvin E1. This interaction triggers a cascade of signaling pathways, including G(i)/G(o), beta-arrestin, intracellular calcium mobilization, and phosphorylation of key enzymes, facilitating diverse biological effects such as immune response modulation, adipogenesis, and angiogenesis.

Therapeutic significance:

Understanding the role of Chemerin-like receptor 1 could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.